Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report
Author:
Publisher
AME Publishing Company
Subject
Anesthesiology and Pain Medicine,Advanced and Specialised Nursing
Link
https://apm.amegroups.com/article/download/67822/pdf
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutations;Respiratory Investigation;2024-05
2. Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non–Small-Cell Lung Cancer: Regulatory Considerations;Journal of Clinical Oncology;2023-08-10
3. Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report;Frontiers in Medicine;2023-06-29
4. Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR ‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance;Respirology Case Reports;2022-10-17
5. New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer;Current Treatment Options in Oncology;2022-10-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3